Neshima Medical Overview
Neshima is developing life-saving treatments for severe lung diseases using LiFT™, a patented foam-based delivery platform. LiFT™ enables deep and uniform therapeutic delivery to the alveoli, overcoming the limitations of inhalers, nebulizers, and intravenous treatments. Our lead applications include a regenerative cell therapy for COPD. As a cost-effective PoC we are also developing an ICU-delivered antibiotic treatment for antimicrobial-resistant infections. A fully functional prototype has been tested in large animals. Neshima is targeting a $10 billion U.S. market with a B2B model.
Latest News
ללא מכונות הנשמה: חוקרים ישראלים מפתחים שיטות פורצות דרך להצלת חולי קורונה
Pioneering foam therapy offers hope to lung patients LIFT Project Results in brief H2020 CORDIS European Commission
https://www.hayadan.org.il/technology-developed-at-the-technion-is-expected-to-significantly-improve-the-effectiveness-of-existing-drugs-in-the-treatment-of-lung-disease-1704202
growth-positive
Israel's Novel Technology Gives New Hope for Coronavirus Patients With Leading Cause of Mortality
Researchers from the Israeli Technion have developed an innovative technology to treat severe COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS). The technology, called Liquid Foam Therapy (LIFT), improves the distribution of surfactant in the lungs and has shown promising results in animal models. The team is now working on constructing a delivery device and plans to conduct preclinical studies in pigs. If successful, the therapy will undergo clinical trials and will be licensed to a newly founded start-up company called Neshima Medical. The development of this treatment could have a positive impact on the Technions growth.
PartnersInvestment
growth-positive
חוקרים בטכניון פיתחו טכנולוגיה שעשויה להציל חולי קורונה קשים
Researchers at the Technion have developed a new technology that significantly improves the effectiveness of existing drugs in treating respiratory diseases, including severe COVID-19 cases. The technology, called Liquid Foam Therapy, enhances the dispersion of surfactant in the lungs, allowing for better distribution and improved respiratory function. The researchers have conducted successful laboratory experiments on pigs and are now working towards completing the development of the medical device and conducting pre-clinical trials. If successful, clinical trials in humans will follow. The technology has also garnered interest from China, where similar experiments will be conducted. The Technions innovation has the potential to save lives and reduce mortality rates from COVID-19.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | neshimamedical.com/ |
Locations
Haifa, Israel
Dimona, Israel
Photos & Videos
No files yet
